How much does Vertical Pharma Resources Limited make?

Vertical Pharma Resources Limited reported revenue of £39.2m and £5.3m profit in the year to 28 Feb 2025, according to its accounts filed at Companies House.

How many employees does Vertical Pharma Resources Limited have?

Vertical Pharma Resources Limited reported an average of 89 employees in the year to 28 Feb 2025.

Is Vertical Pharma Resources Limited profitable?

Yes — Vertical Pharma Resources Limited reported a profit of £5.3m in the year to 28 Feb 2025.

Company No. 06077026 · Incorporated 1 Feb 2007

Vertical Pharma Resources Limited

Registered name: VERTICAL PHARMA RESOURCES LIMITED

Part of Ipsco Limited group

Vertical Pharma Resources Limited made £39.2m revenue and £5.3m profit in the year to 28 Feb 2025. read from filing text

Vertical Pharma Resources Limited’s revenue grew 66% to £39.2m in the year to 28 Feb 2025, with £5.3m profit and 89 employees. The company is classified under “manufacture of pharmaceutical preparations” and is based in West Molesey; we hold 4 years of its filed accounts.

Full P&L filedSection C · ManufacturingSIC 21200Manufacture of pharmaceutical preparations

Status: Active
Location: West Molesey, London
Age: 19 yrs · since 2007
Type: Private Limited Company

Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently. From the filing: “The company's immediate parent undertaking is Integrated Pharmaceutical Services (IPS) Limited. The company's ultimate parent undertaking is IPSCO Limited. Both are registered in England and Wales. Th”

Latest accounts · year to 28 Feb 2025

Key figures

Operating leverage

Revenue

£39.2m

Growth ▲66.3%

Profit

£5.3m

Growth ▲189.6%

Profit margin

13.6%

Gross 30.1%

Employees

Change ▲12.7%

Profit / employee

£59.9k

Revenue/employee £441k

Profitable streak

4yrs

Consecutive profitable years in our data

Badges are automated estimates derived from the filed figures — not statements of fact about the company.

4 filed years

Financial history

Multi-year financials, oldest to newest
Year to	28 Feb 2022	28 Feb 2023	28 Feb 2024	28 Feb 2025
Disclosure	Full P&Lread from filing text	Full P&Lread from filing text	Full P&Lread from filing text	Full P&Lread from filing text
Profit & loss
Revenue (turnover)	£16.3m	£17.2m	£23.6m	£39.2m
Cost of sales	£10.6m	£11.5m	£16.3m	£27.4m
Gross profit	£5.8m	£5.7m	£7.3m	£11.8m
Operating profit	£1.1m	£307k	£1.7m	£4.5m
Profit before tax	£1.3m	−£98.7k	£1.8m	£5.5m
Profit after tax	£1.3m	£6.7k	£1.8m	£5.3m
Profit (best available)	£1.3m	£6.7k	£1.8m	£5.3m
Staff costs	£3.3m	£3.6m	£3.7m	£4.6m
Employees (average)	79	85	79	89
Ratios
Profit margin	8.1%	0%	7.8%	13.6%
Gross margin	35.3%	32.9%	31%	30.1%
Revenue per employee	£207k	£202k	£299k	£441k
Profit per employee	£16.7k	£79	£23.3k	£59.9k
Growth (year on year)
Revenue growth	—	▲5.1%	▲37.3%	▲66.3%
Profit growth	—	▼99.5%	▲27432%	▲189.6%
Headcount growth	—	▲7.6%	▼7.1%	▲12.7%
Balance sheet — indirect signals, not revenue
Cash at bank	£943k	£646k	£1.4m	£2.5m
Net assets	£1.6m	£1.7m	£3.5m	£8.8m
Fixed assets	£256k	£318k	£346k	£3.9m
Current assets	£6.2m	£6.2m	£9.9m	£16.6m
Debtors	£3.9m	£2.7m	£4.7m	£8.2m
Deferred income	£1.2m	£1.4m	£1.5m	£3.5m
Source	FullAccounts · bulk data Dec 2023	FullAccounts · bulk data Dec 2023	FullAccounts · bulk data Jun 2024	FullAccounts · bulk data Jul 2025

Derived from the latest filing

How the business works

Profit margin: 13.6%; Profit ÷ revenue.
Gross margin: 30.1%; Gross profit ÷ revenue. High for software and services.
Revenue per employee: £441k; Revenue ÷ average employees.
Profit per employee: £59.9k; Profit ÷ average employees.
Cash conversion: —; Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
Fixed assets ÷ revenue: 10.1%; Capital intensity. Low = capital-light, cheaper to start.
Deferred income ÷ revenue: 8.9%; Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
Debtors ÷ revenue: 20.8%; Money owed by customers. Low = customers pay quickly.

Indirect — not revenue

Balance-sheet signals

Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.

Net assets: ▲153%; Now £8.8m
Cash at bank: ▲81%; Now £2.5m
Headcount: ▲13%; Now 89
Deferred income: ▲134%; Now £3.5m
Fixed assets: ▲1040%; Now £3.9m

Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.

Corporate ownership

Group structure

Ownership chain

Ipsco Limitedultimate parent75–100%
Integrated Pharmaceutical Services (Ips) Limited75–100%
Vertical Pharma Resources Limitedthis company

Bands show the share of ownership each company holds in the one below it.

Subsidiaries (1)

Integro Medical Clinics LimitedFigures not disclosed

From the Persons with Significant Control register (corporate controllers only).

Same industry, similar size

Similar profitable businesses

Industry benchmarks →

Sources

Companies House profile Filing history & original accounts

Latest figures from FullAccounts for the year to 28 Feb 2025 (profit £5.3m), from the Companies House accounts bulk data published Jul 2025. Spotted an error? Request a correction.

Updated from Companies House on 15 Oct 2026

Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.